You are viewing the site in preview mode

Skip to main content

Table 4 The cumulative and marginal cost - effectiveness and cost – benefit of unsanctioned SIF in Vancouver using Kaplan and O’Keefe’s [34] model

From: Exploring the role of an unsanctioned, supervised peer driven injection facility in reducing HIV and hepatitis C infections in people that require assistance during injection

Variables Annual cost of operation Sharing rate # of HIV averted Cost-effectiveness ratio HIV Benefit-cost ratio HIV
One SIF $97,203 25 % 10 $9,720 21.7
  ($97,203)   (10) ($9,720) (21.7)
Two SIFs $194,406 19 % 19 $10,232 20.6
  ($97,203)   (9) ($10,800) (19.5)
Three SIFs $291,609 18 % 21 $13,886 15.2
  ($97,203)   (2) ($48,601) (4.3)
Four SIFs $388,812 16 % 23 $16,905 12.5
  ($97,203)   (3) ($32,401) (6.5)
Five SIFs $486,015 15 % 27 $18,000 11.7
  ($97,203)   (3) ($32,401) (6.5)
Six SIFs $583,218 13 % 30 $19,441 10.8
  ($97,203)   (3) ($32,401) (6.5)
Seven SIFs $680,421 12 % 32 $21,263 9.9
  ($97,203)   (3) ($32,401) (6.5)
  1. Note: The numbers in parentheses represent the marginal results